UK drugmaker AstraZeneca's COVID-19 vaccine 'likely to protect for a year'
The British drugmaker has already begun human trials of the vaccine developed by the University of Oxford, with a phase I trial in Britain due to end soon and a phase III trial already begun.
The drugmaker has already begun human trials of the vaccine developed by the University of Oxford, with a phase I trial in Britain due to end soon and a phase III trial already begun, Pascal Soriot told broadcaster Bel RTL.
"We think that it will protect for about a year," Soriot said.
AstraZeneca said on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands to supply the European Union with up to 400 million doses of the potential vaccine.
It has also agreed deals with Britain and the United States.
"If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well," Soriot said.
More than 8 million cases of novel coronavirus have been confirmed worldwide, including at least 436,000 deaths, according to a Johns Hopkins University tally.
Meanwhile, a team of scientists at Imperial College London will start the first clinical trials of a potential COVID-19 vaccine this week with more than 45 million pounds in backing from the government and philanthropic donors.
The trials are the first human tests of a new technology which the researchers say could transform vaccine development by enabling rapid responses to emerging diseases such as the COVID-19 infection caused by the new coronavirus.